NCT05791318View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

May 8, 2024

Study Completion Date

May 8, 2024

Conditions
COVID-19
Interventions
DRUG

VYD222

Monoclonal antibody

OTHER

Placebo

Matching Placebo

Trial Locations (1)

6027

Linear Clinical Research, Joondalup

Sponsors

Lead Sponsor

Invivyd, Inc.
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Invivyd, Inc.

INDUSTRY